Compare Orchid Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA vs AJANTA PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA AJANTA PHARMA ORCHID PHARMA/
AJANTA PHARMA
 
P/E (TTM) x -16.5 26.7 - View Chart
P/BV x 2.4 6.3 38.6% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ORCHID PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA
Mar-21
AJANTA PHARMA
Mar-21
ORCHID PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs2,4651,883 130.9%   
Low Rs181,258 1.4%   
Sales per share (Unadj.) Rs110.3334.0 33.0%  
Earnings per share (Unadj.) Rs-28.575.6 -37.8%  
Cash flow per share (Unadj.) Rs-1.989.0 -2.1%  
Dividends per share (Unadj.) Rs09.50 0.0%  
Avg Dividend yield %00.6 0.0%  
Book value per share (Unadj.) Rs159.9346.1 46.2%  
Shares outstanding (eoy) m40.8286.53 47.2%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x11.34.7 239.4%   
Avg P/E ratio x-43.520.8 -209.2%  
P/CF ratio (eoy) x-665.617.7 -3,771.2%  
Price / Book Value ratio x7.84.5 171.1%  
Dividend payout %012.6 0.0%   
Avg Mkt Cap Rs m50,677135,898 37.3%   
No. of employees `000NANA-   
Total wages/salary Rs m6715,483 12.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m4,50128,897 15.6%  
Other income Rs m152260 58.6%   
Total revenues Rs m4,65329,157 16.0%   
Gross profit Rs m2949,986 2.9%  
Depreciation Rs m1,0891,161 93.8%   
Interest Rs m52283 631.3%   
Profit before tax Rs m-1,1659,002 -12.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m02,463 0.0%   
Profit after tax Rs m-1,1656,539 -17.8%  
Gross profit margin %6.534.6 18.9%  
Effective tax rate %027.4 0.0%   
Net profit margin %-25.922.6 -114.4%  
BALANCE SHEET DATA
Current assets Rs m5,49922,178 24.8%   
Current liabilities Rs m1,4218,388 16.9%   
Net working cap to sales %90.647.7 189.9%  
Current ratio x3.92.6 146.4%  
Inventory Days Days2053 37.7%  
Debtors Days Days1,1019 11,799.0%  
Net fixed assets Rs m6,87418,912 36.3%   
Share capital Rs m408174 234.7%   
"Free" reserves Rs m6,12129,777 20.6%   
Net worth Rs m6,52929,951 21.8%   
Long term debt Rs m4,27516 26,718.6%   
Total assets Rs m12,37341,090 30.1%  
Interest coverage x-1.2109.8 -1.1%   
Debt to equity ratio x0.70 122,566.3%  
Sales to assets ratio x0.40.7 51.7%   
Return on assets %-5.216.1 -32.3%  
Return on equity %-17.821.8 -81.8%  
Return on capital %-6.030.3 -19.6%  
Exports to sales %88.10-   
Imports to sales %37.30-   
Exports (fob) Rs m3,966NA-   
Imports (cif) Rs m1,677NA-   
Fx inflow Rs m3,96618,097 21.9%   
Fx outflow Rs m1,7292,315 74.7%   
Net fx Rs m2,23715,782 14.2%   
CASH FLOW
From Operations Rs m2365,763 4.1%  
From Investments Rs m672-2,824 -23.8%  
From Financial Activity Rs m-1,650-3,183 51.8%  
Net Cashflow Rs m-742-244 304.5%  

Share Holding

Indian Promoters % 90.0 70.3 127.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.2 21.5 24.0%  
FIIs % 1.8 9.0 19.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.0 29.7 33.7%  
Shareholders   33,533 57,897 57.9%  
Pledged promoter(s) holding % 32.7 15.4 212.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA With:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    



Today's Market

Sensex, Nifty Recover from Day's Low to End Higher; Maruti Suzuki Hits New High Post Q3 Results(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY22); Net Profit Up 17.6% (Quarterly Result Update)

Jul 31, 2021 | Updated on Jul 31, 2021

For the quarter ended June 2021, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 17.6% YoY). Sales on the other hand came in at Rs 7 bn (up 11.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Jul 8, 2021 | Updated on Jul 8, 2021

Here's an analysis of the annual report of AJANTA PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

5 Hidden Tata Group Companies to Add to Your Watchlist(Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA SHARE PRICE


Jan 25, 2022 (Close)

TRACK ORCHID PHARMA

  • Track your investment in ORCHID PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ORCHID PHARMA - CIPLA COMPARISON

COMPARE ORCHID PHARMA WITH

MARKET STATS